The CHMP Adopts Positive Opinion on Alnylam Pharmaceuticals' Vutrisiran to Treat ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
Shots:
- The CHMP has recommended vutrisiran to treat ATTR-CM adults based on global P-III (HELIOS-B) study assessing it vs PBO in ATTR-CM pts; EC's decision expected in Jun 2025. MAA under PMDA review, with global applications planned in 2025 & beyond
- Study met all ten 1 & 2EPs across both overall & monotx. arms, showing improved outcomes of mortality, CV events & functional capacity with 6min. walk test
- Trial also showed benefits across health status, QoL (Kansas City Cardiomyopathy Questionnaire), plus heart failure symptoms & severity (NYHA class); findings were consistent across all subgroups incl. pts on a concomitant TTR stabilizer. Data was published in The NEJM
Ref: BusinessWire | Image: Alnylam
Related News:- Alnylam Pharmaceuticals Reports the US FDA’s Approval of Amvuttra (Vutrisiran) to Treat ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
